Order Bimatoprost online
Bimatoprost Ophthalmic Solution without prescription
Bimatoprost Ophthalmic Solution without prescription with a brand name Lumigan a topical solution formulated in the form of eye drops. Bimatoprost Ophthalmic Solution without prescription originally was designed to treat glaucoma, ocular hypertension and other medical conditions related to the elevated pleasure within the human eye.
By controlling glaucoma Bimatoprost Ophthalmic Solution without prescription helps to prevent blindness in those case when other medications did not yield positive results. However Bimatoprost Ophthalmic Solution is known to treat condition known as Hypotrichosis, condition commonly attributed to presence of less than normal amount of hair on the body and is known to promote eyelash growth. Bimatoprost is commonly used just for that. Millions of people oall over the world use Bimatoprost in order to increase the length of eyelashes. This ground breaking medicine is approved by FDA and has undergone numerous medical and clinical studies, which proved the effectiveness of the medication.
Bimatoprost Ophthalmic Solution without prescription should be applied to the affected eye once a day typically in the evening. It is very important that the individuals using Bimatoprost Ophthalmic Solution read all the directions very carefully prior to using Bimatoprost Ophthalmic Solution without prescription.
Additionally it is vital that individuals thinking about using Bimatoprost Ophthalmic Solution without prescription generic for Lumigan consult with their doctor for all the necessary facts about the side effects and potential hazards of this medication. Bimatoprost Ophthalmic Solution may control ocular hypertension and glaucoma but is not designed to cure them. Consult with your physician if Bimatoprost Ophthalmic Solution is right for you.
The use of the substance Bimatoprost
Reducing increased IOP in open-angle glaucoma and ophthalmic hypertension in adults (as monotherapy or in combination with beta-blockers).
Treatment of eyelash hypotrichosis (insufficient eyelash growth).
Hypersensitivity; pregnancy; lactation period; age to 18 years.
As anti- glaucoma drugs . Caution should be exercised when using in therapy patients with known risk factors for macular edema (for example, patients with aphakia, patients with artifact and rupture of the posterior lens capsule);
– should be used with caution in patients with severe eye infections and a history of (for example, caused by the herpes simplex virus) or iritis / uveitis;
– there is no experience with bimatoprost in patients with concomitant respiratory dysfunction, which requires caution in such patients. When conducting clinical studies in patients with impaired respiratory function, there was no significant adverse effect on the respiratory system;
– the effect of bimatoprost in patients with heart block is heavier than the first degree or in patients with uncontrolled congestive heart failure has not been studied. A limited number of cases of bradycardia or hypotension have been observed with bimatoprost. Bimatoprost should be used with caution in the treatment of patients predisposed to low heart rate or low blood pressure;
– the effect of bimatoprost in patients with inflammatory diseases of the organ of vision, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma has not been studied.
As a drug for the treatment of eyelash hypotrichosis. Afakia pseudophakia; damage to the posterior lens capsule; the presence of risk factors for macular edema; long course of diabetes; high content of Chs; nephropathy; arterial hypertension, especially with high numbers of DBP; patients with uveitis, in connection with the possible progression of this disease.
Pregnancy and lactation
The FDA category of action for the fetus is C.
There are no data from clinical studies on the use of bimatoprost in pregnant women. According to animal studies, reproductive toxicity has been demonstrated when used in high doses that are toxic to the mother’s body.
In animal studies, oral administration of bimatoprost in a dose that was 33–97 times higher than recommended for topical use showed miscarriages. When used in a dose 41 times higher than the therapeutic, a reduction in the gestation period, an increase in the frequency of fetal death, and a decrease in the body weight of newborns were noted.
The use of bimatoprost during pregnancy is not recommended in the absence of strict indications.
It is not known whether bimatoprost is excreted in human milk. Animal studies have shown that bimatoprost is excreted in breast milk. If it is necessary to use bimatoprost during breastfeeding, a decision must be made to stop breastfeeding or bimatoprost therapy, taking into account the benefits of breastfeeding for the baby and the need for therapy for the mother.
Fertility. There is no information on the effect of bimatoprost on human fertility.
Side effects of the substance Bimatoprost
When used as anti-glaucoma drugs
The following adverse events were noted during clinical studies of bimatoprost in the form of 0.03% eye drops and in the post-registration period.
The frequency of occurrence is given in accordance with the following classification: very often (≥1 / 10); often (≥1 / 100 to </ 10); infrequently (≥1 / 1000 to <1/100); rarely (≥1 / 10000 to <1 / 1,000); very rarely (<1/10000) and with an unknown frequency (cannot be estimated based on available data).
In each group, unwanted effects are presented in decreasing order of severity.
From the nervous system: often – headache; infrequently – dizziness.
From the side of the organs of vision: very often – injection of conjunctival vessels, itching in the eyes, eyelash growth; often – superficial punctate keratitis, corneal erosion, burning eyes, eye irritation, allergic conjunctivitis, blepharitis, decreased visual acuity, dry eye mucosa, redness of the eyelids, eye pain, photophobia, discharge from the eyes, visual impairment, itching of the eyelids, decreased visual acuity, asthenopia, conjunctival edema, sensation of a foreign body in the eye, dry eyes, eye pain, photophobia, lacrimation, discharge from the eyes, blurred vision, increased pigmentation of the iris, darkening of the eyelashes; infrequently – hemorrhagic disorders from the retina, uveitis, cystic macular edema, iritis, blepharospasm, eyelid retraction, periorbital erythema; with unknown frequency – enophthalmos.
From the vessels: often – hypertension.
On the part of the skin and subcutaneous tissues: infrequently – hirsutism.
General disorders and disorders at the injection site: infrequently – asthenia.
Data from laboratory and instrumental studies: often – a deviation from the norm of biochemical parameters of liver function.
In very rare cases, corneal calcification was observed with the use of phosphate-containing eye drops in patients with concomitant significant damage to the cornea.
When used as a medicine for the treatment of eyelash hypotrichosis
General information about adverse reactions when using bimatoprost in the form of 0.03% drops for topical use was obtained in a multicenter randomized, double-blind, placebo-controlled study in parallel groups with 278 adult patients who received therapy with the studied drugs for 4 months.
Itching in the eyes, conjunctival hyperemia, hyperpigmentation of the skin of the eyelids, eye irritation, dry eye syndrome, redness of the eyelids. The listed adverse reactions were observed in less than 4% of cases.
The frequency of occurrence of adverse events according to the data of post-registration application cannot be determined due to the lack of information on the size of the population in which the development of each of the adverse events was noted, as well as the spontaneous nature of reports of adverse events in this period. Additionally, the following adverse reactions were received in the post-registration period: burning sensation of the eyelids, swelling of the conjunctiva, irritation of the eyelids, swelling of the eyelids, itching of the eyelids, hyperpigmentation of the iris, hypersensitivity reactions (local allergic reactions), lacrimation, madarosis and trichorexis (temporary loss of eyelashes from several pieces to entire areas and temporary fragility of the eyelashes, respectively), changes in the skin of the eyelids and periorbital region, including deepening of the folds of the eyelids, spotted rash or erythematous rashes,
Special studies of interaction with other drugs have not been conducted. No interaction is expected in the human body, as systemic concentrations of bimatoprost are extremely low (less than 0.2 ng / ml) after topical application of bimatoprost in ophthalmology.
In clinical trials, bimatoprost was used in conjunction with several different beta-blockers for topical use in ophthalmology, but no interaction was observed.
The simultaneous use of bimatoprost and other anti- glaucoma drugs , except for ophthalmic beta-blockers, has not been studied in studies of the effectiveness and safety of combination therapy.
There was a decrease in the hypotensive effect of bimatoprost in the form of eye drops when used together with other PG analogues in the treatment of ophthalmic hypertension or glaucoma.
There have been no cases of overdose with topical application.
In case of overdose, treatment should be symptomatic and supportive.
Route of administration
Influence on IOP . Bimatoprost reduces IOP when it is instilled directly into the conjunctival cavity of patients with increased IOP . In clinical studies, the use of bimatoprost in the form of drops for topical application was accompanied by a decrease in IOP both in patients with high IOP and with its normal values, but did not reach clinically significant values. With the combined use of bimatoprost in the form of drops for topical application and GHG analogues ( including bimatoprost in the form of eye drops) used to reduce IOPin patients with intraocular hypertension, a decrease in the hypotensive effect is possible. If the patient is receiving treatment analogous GHG necessary advice of the attending physician and monitoring of IOP in the appointment of adjunctive therapy of bimatoprost in the form of drops for topical application.
At-risk groups. Caution should be exercised in patients with acute inflammatory diseases of the inner membranes of the eyeball, for example, with uveitis (since the use of bimatoprost may aggravate the course of inflammation), in patients with aphakia, pseudo-aphakia with rupture of the posterior lens capsule, or with risk factors for macular edema.
Pigmentation of the iris.Perhaps increased pigmentation of the iris, especially with dark pigment, this effect may be irreversible. Increased pigmentation of the iris was observed during instillation of eye drops. The change in pigmentation is primarily associated with an increase in the content of melanin, as well as with an increase in the number of melanocytes. The duration of the pigmentation enhancement effect is unknown. A change in the color of the iris during treatment may go unnoticed for a period from several months to several years. There is no evidence of the clinical significance of increased iris pigmentation in the long term. As a rule, when applying bimatoprost, brown pigmentation around the pupil spreads concentrically to the periphery of the iris, as a result of which the entire iris or individual sectors become more brown. The use of bimatoprost does not affect the accumulation of pigment on the iris of the eye (nevi and freckles). A significant increase in iris pigmentation is not an indication for the abolition of bimatoprost in the form of drops for topical application.
Pigmentation of the skin of the eyelids. Bimatoprost has been reported to cause darkening of the skin of the eyelids and periorbital region.
It is assumed that pigmentation may intensify during the entire period of application of bimatoprost, but in most patients it is reversible and gradually disappears when drugs are canceled .
Hair growth outside the treatment area. Hair growth is possible in those areas of the skin on which bimatoprost was accidentally applied in the form of drops for topical application. It is important to apply drugs only to the skin of the edge of the upper eyelid along the eyelash growth line using the attached sterile applicator; Avoid contact with skin.
In the event of any symptoms of the organ of vision ( including eye injury, an infectious complication), with a sudden decrease in visual acuity, the need for a scheduled ophthalmological operation, and also if undesirable reactions occur, you should contact an ophthalmologist to resolve the issue of the possibility of further treatment with bimatoprost.
With eyelash hypotrichosis, the effect of treatment develops gradually, in most patients within 2 months. Patients should be warned that the effect of bimatoprost is unstable, and a gradual return to its original state after stopping the use of drugs is expected . In addition, there may be differences in the length of the eyelashes, their thickness, color intensity, the total number of eyelashes or uneven growth, and / or a change in the direction of eyelash growth.
Influence on the ability to drive vehicles and work with mechanisms. Bimatoprost has little effect on the ability to drive vehicles and work with mechanisms. As with other eye drops, if temporary blurring of vision occurs after instillation, it is necessary to wait until the clarity of visual perception is restored before driving or operating machinery.